VTX958 Versus Placebo for the Treatment of Moderate to Severe Psoriasis

Summary

This is a study to understand if taking VTX958 is safe and effective in participants diagnosed with moderate to severe psoriasis (PsO). Approximately 200 patients will take VTX958 Dose A, VTX958 Dose B, VTX958 Dose C, VTX958 Dose D, or placebo. The study consists of a 30-day Screening Period (to see if a participant qualifies for the study), a 16-week double-blind period (a participant receives active Dose A, Dose B, Dose C, Dose D, or placebo), a 16-week Long Term Extension (LTE) period, a 36-week Open Label Extension (OLE) period and a 4-week Follow-Up Period. The maximal duration of treatment will be approximately 16 months.

Timeline

Start

2022-11-17

Primary completion

2023-09-25

Completion

2023-12-20

Outcome

Outcome not reported

Stopped (Business): “Business Decision”

Drugs

Indications